What's new? Log in Free sign up

Belite Bio (BLTE)

Company Profile

Company profile

Ticker

BLTE

Exchange

Website

CEO

Dr. Yu-Hsin Lin M.B.A., Ph.D.

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Teva Pharmaceutical Industries Limited • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb • Viatris • AbbVie • Bausch Health Companies ...

Former names

Innovative International Acquisition Corp.

SEC CIK

Corporate docs

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

BLTE stock data

1M 3M 6M 1Y

Analyst ratings and price targets

Last 3 months

Latest filings (excl ownership)

View all

Belite Bio Announces Interim Analysis Results from the Pivotal Global Phase 3 DRAGON trial of Tinlarebant in Adolescent Stargardt Disease Subjects

Prospectus supplement for primary offering

Belite Bio Announces Registered Direct Offering of $15 Million

Prospectus with selling stockholder info

Automatic shelf registration (foreign)

Belite Bio Reports Third Quarter 2024 Financial Results and Provides a Corporate Update

Current report (foreign)

Registration of securities for employees

Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer

Belite Bio Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

Transcripts

View all

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Latest ownership filings

View all

Lin Bioscience International Ltd.

Notice of proposed sale of securities

Notice of proposed sale of securities

Notice of proposed sale of securities

Notice of proposed sale of securities

Notice of proposed sale of securities (amended)

Notice of proposed sale of securities (amended)

Notice of proposed sale of securities

Notice of proposed sale of securities

Financial summary

Financial statements Chart BLTE financial data

Quarter (USD)	Dec 23	Dec 22
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 23	Dec 22
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Belite Bio earnings reports.

Institutional ownership, Q3 2024

BLTE institutional ownership history Ownership history

55.4% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	6	12	-50.0%
Opened positions	1	2	-50.0%
Closed positions	7	1	+600.0%
Increased positions	2	2	–
Reduced positions	0	6	EXIT

13F shares	Current	Prev Q	Change
Total value	720.54 mm	8.28 bn	-91.3%
Total shares	17.11 mm	17.28 mm	-1.0%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Lin Bioscience International	17.10 mm	$0.00	0.0%
Geode Capital Management	6.70 k	$314.10 mm	0.0%
JPM JPMorgan Chase & Co.	6.36 k	$297.97 mm	+7122.7%
Rhumbline Advisers	1.44 k	$67.27 mm	NEW
GAMMA Investing	871.00	$40.83 mm	+103.5%
Advisor	8.00	$375.00 k	0.0%
Proequities	0.00	$0.00

Largest transactions	Shares	Bought/sold	Change
Armistice Capital	0.00	-148.00 k	EXIT
STT State Street	0.00	-15.67 k	EXIT
Point72 Asset Management	0.00	-7.31 k	EXIT
JPM JPMorgan Chase & Co.	6.36 k	+6.27 k	+7122.7%
HRT Financial	0.00	-5.41 k	EXIT
Virtus ETF Advisers	0.00	-1.81 k	EXIT
Rhumbline Advisers	1.44 k	+1.44 k	NEW
MS Morgan Stanley	0.00	-1.04 k	EXIT
GAMMA Investing	871.00	+443.00	+103.5%
BAC Bank of America	0.00	-102.00	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

News

From Benzinga Pro

Belite Bio's Tinlarebant Trial For Stargardt Disease Advances As DSMB Recommends Continuation Without Modifications

An independent Data Safety Monitoring Board (DSMB) for the Phase 3 DRAGON trial recommends trial continuation without any modifications, maintaining the sample size at 104 subjects following a planned interim efficacy

Reported Earlier, Belite Bio Raises $15M Via Registered Direct Offering Of 258,309 ADSs And Warrants At $58.07 Per ADS

The Company intends to use the net proceeds from the offering for working capital and general corporate purposes.

Benchmark Maintains Buy on Belite Bio, Raises Price Target to $79

Benchmark analyst Bruce Jackson maintains Belite Bio (NASDAQ:BLTE) with a Buy and raises the price target from $57 to $79.

Press releases

From Benzinga Pro

Belite Bio Announces Interim Analysis Results from the Pivotal Global Phase 3 DRAGON trial of Tinlarebant in Adolescent Stargardt Disease Subjects

An independent Data Safety Monitoring Board (DSMB) for the Phase 3 DRAGON trial recommends trial continuation without any modifications, maintaining the sample size at 104 subjects following a planned interim efficacy

Belite Bio Announces Registered Direct Offering of $15 Million

SAN DIEGO, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc ("BLTE" or the "Company") (NASDAQ:BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.